Systematic review of the impact of HbA1c on outcomes following surgery in patients with diabetes mellitus

Rollins, Katie E.; Varadhan, Krishna K.; Dhatariya, Ketan; Lobo, Dileep N.

doi:10.1016/j.clnu.2015.03.007

Cited by 100 publications

(79 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Poor preoperative glycaemic control, as measured by elevated HbA1c concentrations, has been associated with poor surgical outcomes for emergency and elective patients in many surgical specialities [6,[13][14][15][16][17]18 & ]. These include increased rates of postoperative complications such as surgical site infection, systemic infections, urinary tract infection and lower respiratory tract infection, acute kidney injury, acute coronary syndrome, pneumonia, admission to intensive care, prolonged length of stay, and death.…”

Section: Long-term Glycaemic Control and Outcomementioning

confidence: 99%

The impact of glycaemic variability on the surgical patient

Dhatariya

Levy

Hall

2016

Current Opinion in Anaesthesiology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Long-term Glycaemic Control and Outcomementioning

confidence: 99%

The impact of glycaemic variability on the surgical patient

Dhatariya

Levy

Hall

2016

Current Opinion in Anaesthesiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…DM frequently induces atherosclerosis, which is accompanied by complications such as CI and CVD. Therefore, prevention of CI and CVD has been attempted by using DM markers, which are blood glucose, glycoalbumin and glycohemoglobin (HbA1c) [8]. However, despite frequent application for diagnosis, prevention of the onset remains unsuccessful.…”

Section: Introductionmentioning

confidence: 99%

Association of Serum Antibody Levels against TUBB2C with Diabetes and Cerebral Infarction

Hiwasa

Zhang²,

Kimura³

et al. 2015

Gratis Journal of Biomedical Sciences

View full text Add to dashboard Cite

Cerebral infarction (CI), cardiovascular disease (CVD), diabetes mellitus (DM) and chronic kidney disease (CKD) are atherosclerosis-related diseases, which are major causes of health damage. For early and sensitive diagnosis, development of novel biomarkers is expected and of significant practical importance. First screening was carried out by phage expression cloning to identify antigen proteins recognized by serum IgG antibodies in patients with atherosclerosis. RPA2, LRPAP1, EEF1A1, SPOCK1, LOC729260, tubulin beta 2C (TUBB2C) and KIAA0020 markers were identified. We then compared the serum antibody levels against the candidate proteins between healthy donors (HD) and patients with CI, CVD, DM, or CKD by Alpha (amplified luminescent proximity homogeneous assay)-LISA method. The results showed that the serum TUBB2C antibody levels were significantly higher in patients with CI, DM, or CKD than those in HD. Using the average + 2SD of HD as the cut-off value, the positive thresholds of TUBB2C antibody markers were 14.8% in CI, 25.8% in DM, and 18.3% in CKD. TUBB2C antibody levels were well correlated with artery stenosis degrees such as plaque score, maximum intima-media thickness and cardio ankle vascular index. Consequently, TUBB2C antibody markers are useful to diagnose atherosclerosis, DM, and CKD, and can be applied to the prediction of the onset of CI. The serum anti-TUBB2C antibody markers are useful for the diagnosis of DM and CKD.

show abstract

“…However, this method is less sensitive than enzymatic assays, although considerable recent progress has been made. Therefore, ELISAs are limited to analyze abundant proteins, such as C-reactive protein (CRP) [1], glycated hemoglobin (HbA1c) [2], and adiponectin [3]. Notably, recent remarkable advances in biotechnology, particularly in the polymerase chain reaction methodology, have enabled the highly sensitive detection of nucleic acids, such as cell-free DNA and RNA, in the blood [4].…”

Section: Introductionmentioning

confidence: 99%

Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis

Hiwasa¹,

Tomiyoshi²,

Nakamura³

et al. 2017

Immunome Res

214

179

View full text Add to dashboard Cite

Background: The discovery and development of novel biomarkers that could facilitate early diagnosis and thus prevent the progression of atherosclerosis-related diabetes mellitus (DM), cerebral infarction (CI), and cardiovascular disease (CVD) has garnered much research interest. Notably, recent reports have described a number of highly sensitive antibody markers. In this study, we aimed to identify additional antibody markers that would facilitate screening. Methods:The amplified luminescent proximity homogeneous assay (AlphaLISA) method, which incorporates glutathione-or streptavidin-donor beads and anti-human-IgG-acceptor beads, was used to evaluate serum antibody levels in serum samples. The protein array method was used for the initial screening, and peptide arrays were used to identify epitope sites. Results:The protein array identified SH3 domain-binding protein 5 (SH3BP5) as a target antigen of serum IgG antibodies in the sera of patients with atherosclerosis. We prepared recombinant glutathione S-transferase (GST)-fused SH3BP5 protein. Peptide arrays revealed that the epitope site recognized by serum antibodies is located within amino acids 161-174 of SH3BP5. AlphaLISA revealed significantly higher serum antibody levels against both the SH3BP5 protein and peptide in patients with DM, acute-phase CI, transient ischemic attack, CVD or chronic kidney disease (CKD), than in healthy donors. Furthermore, areas under the receiver operating characteristic curves of these antibodies were higher in patients with CKD and DM than in other patients. Spearman correlation analysis revealed associations between the serum antibody levels against SH3BP5 peptide and artery stenosis, hypertension, and smoking. Conclusions:The serum anti-SH3BP5 antibody marker appears to be useful for estimating the progress of atherosclerosis and may discriminate atherosclerosis associated with hypertension and/or habitual smoking.

show abstract

Systematic review of the impact of HbA1c on outcomes following surgery in patients with diabetes mellitus

Cited by 100 publications

References 46 publications

The impact of glycaemic variability on the surgical patient

The impact of glycaemic variability on the surgical patient

Association of Serum Antibody Levels against TUBB2C with Diabetes and Cerebral Infarction

Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis

Contact Info

Product

Resources

About